Abstract:Fundamentally, cancer arises from genetic and epigenetic alterations that interplay to reprogram gene expression networks, leading to unrestrained proliferation. Glioblastoma (GBM) is the most prevalent and aggressive primary brain cancer, with a median survival of approximately one year and a 5-year survival rate of just 5%. The standard care for GBM patients has remained unchanged for decades, underscoring the need for a better understanding of GBM biology to develop more effective therapies. The relatively low genetic mutation burden in GBM highlights the significant role of epigenetic mechanisms in its pathogenesis. Our recent work shows that chromatin remodeling plays pivotal roles in GBM pathogenesis. The BRD8-driven EP400 chromatin remodeling complex maintains GBM by crippling p53-mediated tumor suppression in an unprecedented way through hijacking the histone variant H2AZ at p53 target loci, enforcing a repressive chromatin state that prevents p53-mediated transactivation. Targeting BRD8 in TP53 WT GBM, which makes up ~71% of all GBM cases, enhances chromatin accessibility by evicting H2AZ. This restores p53-mediated transactivation of its targets, reestablishes cell cycle arrest, inhibits gliomagenesis, and prolongs survival in xenograft models of TP53 WT GBM. Conversely, the NuRD chromatin remodeling complex driven by CHD5 governs the MYC-mediated oncogenic network to prevent gliomagenesis. Mechanistically, CHD5 forms a CHD3-containing but CHD4-independent NuRD complex that directly binds to the MYC promoter and super enhancers. Chd5 loss triggers the remodeling of chromatin, enhances chromatin accessibility at Myc loci, augments Myc expression, significantly impairs NSCs differentiation while promotes proliferation, transformation, and gliomagenesis in vivo . Furthermore, reactivating CHD5 in human GBM xenograft models significantly extends survival. Thus, our findings reveal previously unappreciated epigenetic mechanisms by which GBM cells reprogram both tumor-suppressive and oncogenic transcription networks to facilitate their outgrowth. This sheds new light on our understanding of GBM malignancy and provides promising therapeutic opportunities for treating patients with this devastating malignancy.

CRMP2 Phosphorylation Drives Glioblastoma Cell Proliferation

CRB2 enhances malignancy of glioblastoma via activation of the NF-κB pathway

Cyclic nucleotide phosphodiesterase-1C (PDE1C) drives cell proliferation, migration and invasion in glioblastoma multiforme cells in vitro

Csig-25. Mapk/Erk Signaling In Gliomas Modulates Interferon Responses, Promotes Tumor-Microglia Crosstalk, And Confers Susceptibility To Anti-Pd-1 And Anti-Ctla-4 Immunotherapy

NFS-10. ROLE OF CDKN2A CO-DELETION IN DRIVING TUMOR INVASIVENESS IN NF1 MUTANT GLIOMA

Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival

MOB2 suppresses GBM cell migration and invasion via regulation of FAK/Akt and cAMP/PKA signaling

Haploinsufficiency of Adenomatous Polyposis Coli Coupled with Kirsten Rat Sarcoma Viral Oncogene Homologue Activation and P53 Loss Provokes High-Grade Glioblastoma Formation in Mice

Repression of PCGF1 Decreases the Proliferation of Glioblastoma Cells in Association with Inactivation of C-Myc Signaling Pathway

Nonstructural Maintenance of Chromatin Condensin I Complex Subunit G Promotes the Progression of Glioblastoma by Facilitating Poly (Adp-Ribose) Polymerase 1-Mediated E2F1 Transactivation

Supplementary Figures S1-S8 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2

Activity of Metabotropic Glutamate Receptor 4 Suppresses Proliferation and Promotes Apoptosis with Inhibition of Gli-1 in Human Glioblastoma Cells.

Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme

Therapy-resistant and -Sensitive Lncrnas, SNHG1 and UBL7-AS1 Promote Glioblastoma Cell Proliferation.

RCC2 Promotes Proliferation and Radio-Resistance in Glioblastoma Via Activating Transcription of DNMT1.

Epco-27. Chromatin Remodeling Reprograms The Transcription Network In Glioblastoma

Up-regulation of PDGF-D and NRP-1 in the Glioma Cell Line 1321N1 Attributed to Sialic Acid Treatment: Mini-review and Findings

CRMP1 Inhibits Proliferation of Medulloblastoma and is Regulated by HMGA1

Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma

Knockdown of CREB3 activates endoplasmic reticulum stress and induces apoptosis in glioblastoma.

Drug Resistance in Glioma Cells Induced by a Mesenchymal–Amoeboid Migratory Switch